The molecular classification of medulloblastoma: driving the next generation clinical trials

Area of Science:

• Pediatric oncology
• Neuro-oncology
• Genomics

Background:

• Medulloblastoma, a common pediatric brain tumor, has seen improved cure rates (approx. 70%) due to advances in multimodal therapy.
• The pace of cure rate improvement has slowed, indicating limitations of current cytotoxic therapies and clinical risk stratification.
• Significant long-term toxicities associated with current treatments necessitate novel therapeutic approaches.

Purpose of the Study:

• To explore the potential of targeted biologic therapies for medulloblastoma.
• To highlight the need for a paradigm shift in disease classification and study for improved outcomes.
• To address the slowing progress in increasing cure rates and managing treatment toxicity.

Main Methods:

• Genome-based high-throughput analytic techniques were employed.
• Independent research groups reported novel molecular classification methods for medulloblastoma.
• A consensus emerged for classifying medulloblastoma into four molecular subtypes.

Main Results:

• Four molecular subtypes of medulloblastoma have been identified: wingless-type (WNT) pathway subtype, Sonic Hedgehog (SHH) pathway subtype, and two less defined subtypes (Groups C and D).
• This molecular classification provides a new framework for understanding medulloblastoma heterogeneity.
• The findings pave the way for subtype-specific treatment strategies.

Conclusions:

• A novel classification and risk stratification based on biologic subtypes are essential for future medulloblastoma research.
• Identifying specific subtypes will guide research focus and the development of targeted therapies.
• This approach holds promise for increasing cure rates and decreasing long-term treatment toxicity in pediatric medulloblastoma.